<DOC>
	<DOCNO>NCT01387854</DOCNO>
	<brief_summary>There limited information long-term effect treat patient MPS VI NaglazymeÂ® limit data natural history treat untreated MPS VI patient . The Re-survey Study ASB-00-03 assist understand effect long-term Naglazyme treatment natural history MPS VI patient population .</brief_summary>
	<brief_title>Observational Study Patients With Mucopolysaccharidosis ( MPS ) VI Who Previously Participated ASB-00-02</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<criteria>Willing able provide write , sign informed consent , case patient age 16 year , provide write assent ( require ) write informed consent legally authorize representative nature study explain , prior researchrelated procedure . Previously participate Survey Study ASB0002 , meet criterion MPS VI diagnosis . Willing perform study assessment procedures physically possible . Concurrent disease condition would interfere study participation safety . Any condition , view Investigator would place patient high risk complete study . Concurrent enrollment randomization clinical study MPS VI treatment . Patients enrol BioMarin MPS VI Clinical Surveillance Program may enrol Resurvey Study ASB0003 .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>